These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 30056080)
1. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080 [TBL] [Abstract][Full Text] [Related]
2. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270 [TBL] [Abstract][Full Text] [Related]
3. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer. Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214 [TBL] [Abstract][Full Text] [Related]
4. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial. Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457 [TBL] [Abstract][Full Text] [Related]
5. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303 [TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510 [TBL] [Abstract][Full Text] [Related]
7. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer. Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199 [TBL] [Abstract][Full Text] [Related]
8. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578 [TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836 [TBL] [Abstract][Full Text] [Related]
10. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. Magli A; Farneti A; Faiella A; Ferriero M; Landoni V; Giannarelli D; Moretti E; de Paula U; Gomellini S; Sanguineti G Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):93-100. PubMed ID: 33745951 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial. Wages NA; Sanders JC; Smith A; Wood S; Anscher MS; Varhegyi N; Krupski TL; Harris TJ; Showalter TN Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1254-1262. PubMed ID: 33227441 [TBL] [Abstract][Full Text] [Related]
12. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer. Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807 [TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994 [TBL] [Abstract][Full Text] [Related]
14. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Hanlon AL; Watkins Bruner D; Peter R; Hanks GE Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497 [TBL] [Abstract][Full Text] [Related]
15. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839 [TBL] [Abstract][Full Text] [Related]
17. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. Pan X; Levin-Epstein R; Huang J; Ruan D; King CR; Kishan AU; Steinberg ML; Qi XS Radiother Oncol; 2020 Jul; 148():181-188. PubMed ID: 32388444 [TBL] [Abstract][Full Text] [Related]
18. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751 [TBL] [Abstract][Full Text] [Related]
19. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426 [TBL] [Abstract][Full Text] [Related]
20. Proctitis following stereotactic body radiation therapy for prostate cancer. Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]